REG - N4 Pharma PLC - Result of AGM

N4 PharmaAnnouncement

03/04/2023 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230403:nRSC1932Va&default-theme=true

RNS Number : 1932V  N4 Pharma PLC  03 April 2023

3 April 2023

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Result of Annual General Meeting

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to announce that at its annual general meeting ("AGM"), held earlier
today, all resolutions were duly passed.

 

 Resolution                                                                      For         For%    Against  Against %  Total       Witheld votes*
 Ordinary Resolution 1 - To receive the annual report and audited accounts for   20,267,523  99.37%  127,579  0.63%      20,395,102  19,729
 the year ended 31 December 2022
 Ordinary Resolution 2 - To re-elect John Chiplin as a Director of the Company   20,004,322  98.08%  390,780  1.92%      20,395,102  19,729
 Ordinary Resolution 3 - To re-elect Luke Cairns as a Director of the Company    20,165,927  98.88%  229,175  1.12%      20,395,102  19,729
 Ordinary Resolution 4 - To re-elect Chris Britten as a Director of the Company  20,004,322  98.87%  229,175  1.13%      20,233,497  181,334
 Ordinary Resolution 5 - To re-appoint Saffery Champness LLP as the Companyʼs    20,037,518  98.25%  356,384  1.75%      20,393,902  20,929
 auditor and to authorise the Directors to determine their remuneration
 Ordinary Resolution 6 - To authorise the Directors to allot shares              19,996,465  98.36%  333,237  1.64%      20,329,702  85,129
 Special Resolution 7 - To disapply pre-emption rights                           20,003,065  98.39%  326,437  1.61%      20,329,502  85,329

 

*Please note a vote withheld is not a vote in law and is not counted in the
calculation of votes validly cast for or against a resolution.

 

 

Enquiries:

 

 N4 Pharma plc
 Nigel Theobald, CEO                                         Via IFC Advisory
 Luke Cairns, Executive Director

 SP Angel Corporate Finance LLP                              Tel: +44(0)20 3470 0470
 Nominated Adviser and Joint Broker
 Matthew Johnson/Kasia Brzozowska (Corporate Finance)
 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

 Turner Pope Investments (TPI) Limited                       Tel: +44(0)20 3657 0050
 Joint Broker
 Andy Thacker

 James Pope

 IFC Advisory Ltd                                            Tel: +44(0)20 3934 6630
 Financial PR
 Graham Herring
 Zach Cohen

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for cancer and vaccine treatments using its unique silica nanoparticle
delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens for cancer and vaccine treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity.  As these products progress through preclinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBXGDSIGGDGXX